New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet – Phase 1 Data Indicate Potential for Use of Once ...